Adaptimmune Therapeutics (ADAP)
(Real Time Quote from BATS)
$1.20 USD
+0.04 (3.45%)
Updated Jul 9, 2024 01:20 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
ADAP 1.20 +0.04(3.45%)
Will ADAP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ADAP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADAP
Adaptimmune (ADAP) Down on End of Collaboration With Roche
Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know
ADAP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for ADAP
Adaptimmune Enhances Executive Severance and Benefit Terms
Adaptimmune Therapeutics (ADAP) Gets a Buy from TD Cowen
Buy Rating for Adaptimmune on Strong Partnership Potential and Financial Upside
Adaptimmune’s Strategic Collaboration with Galapagos: A Cautious Hold Amid Promising Developments
Biotech Alert: Searches spiking for these stocks today